| Recruiting | Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Re NCT07166419 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Recruiting | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558 | Lyell Immunopharma, Inc. | Phase 3 |
| Not Yet Recruiting | Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymp NCT07159906 | First Affiliated Hospital of Zhejiang University | Phase 1 / Phase 2 |
| Recruiting | Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527 | AIDS Malignancy Consortium | Phase 1 |
| Recruiting | A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL NCT06484920 | Rita Assi | Phase 2 |
| Recruiting | SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265 | Verismo Therapeutics | Phase 1 |
| Recruiting | Emapalumab Prevention of CAR-T Cell Associated Toxicities NCT06550141 | Marcela V. Maus, M.D.,Ph.D. | Phase 2 |
| Recruiting | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) NCT06343311 | Estrella Biopharma, Inc. | Phase 1 / Phase 2 |
| Recruiting | Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT05967416 | SIRPant Immunotherapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Ly NCT06097455 | Fundacion Clinic per a la Recerca Biomédica | EARLY_Phase 1 |
| Recruiting | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Recruiting | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Can NCT06119685 | Indapta Therapeutics, INC. | Phase 1 / Phase 2 |
| Recruiting | A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematologic NCT05892718 | FBD Biologics Limited | Phase 1 |
| Active Not Recruiting | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies NCT05828589 | BeOne Medicines | Phase 1 |
| Recruiting | Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma NCT05826535 | Lyell Immunopharma, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma NCT05621096 | University of Nebraska | Phase 1 |
| Active Not Recruiting | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have R NCT05627245 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin' NCT05260957 | Lazaros Lekakis | Phase 2 |
| Recruiting | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lym NCT05418088 | Sumithira Vasu | Phase 1 |
| Active Not Recruiting | Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma NCT05053659 | Paolo Caimi, MD | Phase 1 |
| Recruiting | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119 | Children's Oncology Group | Phase 1 / Phase 2 |
| Unknown | Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non- NCT05420493 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Active Not Recruiting | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neop NCT04640779 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter NCT04284774 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity NCT04150913 | Marcela V. Maus, M.D.,Ph.D. | Phase 2 |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma NCT04545762 | C. Babis Andreadis | Phase 1 |
| Unknown | A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma NCT04923789 | The First Affiliated Hospital of Soochow University | — |
| Unknown | A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma NCT04539444 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Active Not Recruiting | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat NCT04195555 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | CD19-Specific T Cells Post AlloSCT NCT03579888 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in P NCT04205409 | University of Washington | Phase 2 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Withdrawn | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, NCT04029038 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma NCT04012892 | Chinese PLA General Hospital | Phase 1 |
| Active Not Recruiting | 9-ING-41 in Patients With Advanced Cancers NCT03678883 | Actuate Therapeutics Inc. | Phase 2 |
| Unknown | Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lym NCT03719989 | Seoul National University Hospital | Phase 2 |
| Unknown | MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin NCT03778619 | GC Cell Corporation | Phase 1 / Phase 2 |
| Active Not Recruiting | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi NCT03698994 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participa NCT03583424 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly NCT03526250 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03210714 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi NCT03213652 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma NCT03892421 | La Raza Medical Center | Phase 1 / Phase 2 |
| Terminated | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory No NCT03432741 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma NCT03479268 | City of Hope Medical Center | Phase 1 |
| Completed | Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin NCT03210662 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03213678 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03220035 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lympho NCT03213691 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213704 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | CAR-T for R/R B-NHL NCT03196830 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Completed | Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma NCT02568553 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HS NCT02728700 | Stanford University | Phase 1 |
| Terminated | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT02420795 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Intra-Osseous Co-Transplant of UCB and hMSC NCT02181478 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or NCT02304458 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non- NCT01865617 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Unknown | NK Cells in Cord Blood Transplantation NCT01619761 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma NCT01703949 | University of Washington | Phase 2 |
| Unknown | Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma NCT01811368 | Joseph Tuscano | Phase 2 |
| Completed | Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or R NCT01381692 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients NCT01008462 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL NCT03042585 | Loyola University | N/A |
| Completed | A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cel NCT00521560 | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | Phase 2 |
| Completed | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or R NCT00005803 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |